Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Side Effects of TepotinibPatients should schedule regular follow-ups during trea···【more】
Release date：2026-03-24Recommended：41
On May 28, 2021, Amgen announced that the U.S. Food and Drug Administration (FDA···【more】
Release date：2026-03-23Recommended：48
On January 17, 2025, Amgen announced that the U.S. Food and Drug Administration ···【more】
Release date：2026-03-23Recommended：54
KRAS mutations have long been considered a major challenge in cancer research, r···【more】
Release date：2026-03-23Recommended：49
Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated ap···【more】
Release date：2026-03-23Recommended：40
Cabozantinib (Cabometyx) was first approved by the FDA in 2012. It is a non‑spec···【more】
Release date：2026-03-20Recommended：54
On March 26, 2025, Exelixis, Inc. announced that the U.S. Food and Drug Administ···【more】
Release date：2026-03-20Recommended：74
Cabozantinib is a small-molecule multi-targeted tyrosine kinase inhibitor develo···【more】
Release date：2026-03-20Recommended：50
Cabozantinib is a broad‑spectrum multi‑targeted anticancer drug that inhibits at···【more】
Release date：2026-03-20Recommended：41
Lorlatinib is a novel, third-generation, small-molecule dual ALK/ROS1 inhibitor ···【more】
Release date：2026-03-19Recommended：63
Lorlatinib was first approved in Japan in September 2018, followed by approval f···【more】
Release date：2026-03-19Recommended：119
Dabrafenib is a selective BRAF serine-threonine kinase inhibitor that exerts ant···【more】
Release date：2026-03-19Recommended：58
